These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19922634)

  • 1. International Active Surveillance Study of Women Taking Oral Contraceptives (INAS-OC Study).
    Dinger JC; Bardenheuer K; Assmann A
    BMC Med Res Methodol; 2009 Nov; 9():77. PubMed ID: 19922634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives.
    Dinger J; Möhner S; Heinemann K
    Contraception; 2016 May; 93(5):378-85. PubMed ID: 26825258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives.
    Dinger J; Bardenheuer K; Heinemann K
    Contraception; 2014 Apr; 89(4):253-63. PubMed ID: 24576793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
    Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
    Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives.
    Loughlin J; Seeger JD; Eng PM; Foegh M; Clifford CR; Cutone J; Walker AM
    Contraception; 2008 Nov; 78(5):377-83. PubMed ID: 18929734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women.
    Lewis MA; Heinemann LA; Spitzer WO; MacRae KD; Bruppacher R
    Contraception; 1997 Sep; 56(3):129-40. PubMed ID: 9347202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study.
    Dinger J; Assmann A; Möhner S; Minh TD
    J Fam Plann Reprod Health Care; 2010 Jul; 36(3):123-9. PubMed ID: 20659364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smoking and use of oral contraceptives: impact on thrombotic diseases.
    Lidegaard O
    Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S357-63. PubMed ID: 10368521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of oral contraceptive progestins on serum copper concentration.
    Berg G; Kohlmeier L; Brenner H
    Eur J Clin Nutr; 1998 Oct; 52(10):711-5. PubMed ID: 9805216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study.
    Kelly S; Davies E; Fearns S; McKinnon C; Carter R; Gerlinger C; Smithers A
    Clin Drug Investig; 2010; 30(5):325-36. PubMed ID: 20384388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes.
    Mona Eng P; Seeger JD; Loughlin J; Oh K; Walker AM
    Contraception; 2007 Feb; 75(2):101-7. PubMed ID: 17241838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
    Marr J; Gerlinger C; Kunz M
    Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of a new oral contraceptive containing drospirenone.
    Heinemann LA; Dinger J
    Drug Saf; 2004; 27(13):1001-18. PubMed ID: 15471507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive.
    Keam SJ; Wagstaff AJ
    Treat Endocrinol; 2003; 2(1):49-70. PubMed ID: 15871554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women.
    Koetsawang S; Charoenvisal C; Banharnsupawat L; Singhakovin S; Kaewsuk O; Punnahitanont S
    Contraception; 1995 Apr; 51(4):225-9. PubMed ID: 7796587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives.
    Fruzzetti F; Ricci C; Fioretti P
    Contraception; 1994 Jun; 49(6):579-92. PubMed ID: 8070263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen and progestin components of oral contraceptives: relationship to vascular disease.
    Carr BR; Ory H
    Contraception; 1997 May; 55(5):267-72. PubMed ID: 9220222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation.
    Dinger JC; Heinemann LA; Kühl-Habich D
    Contraception; 2007 May; 75(5):344-54. PubMed ID: 17434015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
    Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.